Arginase Deficiency Clinical Trials

A listing of Arginase Deficiency medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

Stanford
Palo Alto California

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

District of Columbia

Children’s National
Washington District of Columbia

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Florida

University of Florida
Gainesville Florida

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Michigan

Children’s Hospital of Michigan
Detroit Michigan

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

New York

Mt. Sinai
New York New York

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Pennsylvania

Children’s Hospital of Pittsburgh
Pittsburgh Pennsylvania

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Texas

University of Texas Southwestern
Dallas Texas

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Utah

University of Utah
Salt Lake City Utah

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Washington

Seattle Children’s Hospital
Seattle Washington

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Canada

SickKids
Toronto International

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102